by start some you, QX our additional on results. Thank I providing Tom. commentary will
growth growth was our benefits by the which revenue prices business, by customers existing driven organic, XXXX. of implemented increased entirely mostly DPNCheck year-over-year was overall utilization of higher our XX%. and Our about reflecting in grew X% This
Bell, commercial therefore this joined market impact XXXX. Population Su the focuses will XXXX. X SVP from & Medicare felt in to of starting team new the we Value utilization Advantage our in are value-based led is the The who This operations. DPNCheck which team team long Care first Medicare commercial bulk by October Based and and that sales of and the be is in highly clinical commercial Over sales, cycle Health in marketing value-based experienced individuals the course built Advantage quarter, on care our our – team,
with ADVANCE as QX are quality the contribution. sales the they However, lines, managed, other are of and the currently Revenue in operating pleased pipeline. our and for contracted activities Quell provided we positive two product depth and
Our year. expectation drag this will products of these both remain a is on that growth
are discuss. we I for regulatory Quell outcome which in will subject positive resume planning a growth XXXX to to However,
of received FDA novo designation a being request, symptoms it this indication de of in we agency XXXX pain As October of submitted was platform, the noted currently the couple with for we We prescription under fibromyalgia. over the by treatment past which neurotherapeutic from have the a of Quell chronic is and over-the-counter years, July extremity non-specific focused breakthrough of reviewed starting a treatment XXXX. transitioning lower are for to in
have expect We in the a with next the several interactions had months. FDA several and decision
FDA If must will we is no receive with be then first only and individuals Quell there which indication, specific this However, for the fibromyalgia. non-pharmacologic the meet. timeline treatment
year conduct limited occur a with of fourth If the would to these be Quell proceed timing this and to a XXXX. launch planning in full in as resume in planned XXXX and events determined. quarter revenue launch are We to the exact still growth
I symptoms. the Quell alluded Moving which most on now for novo the to to to, de receiving near-term of the is market important just fibromyalgia is the treatment authorization FDA milestones, one
months. I we several hear As noted, the expecting are next to in
induced NIH for and to trial upcoming peripheral complete Cancer or enrollment. controlled milestone funded CIPN Institute important in National neuropathy of randomized is Another chemotherapy the Quell
exact challenging the the has with certain not COVID-XX. due timing study throughout as to are patient been recruitment We
and study it year, out will disclosure end preliminary However, the up of by first definitely of of the seems XXXX. that findings but the come mid-year. results some wrap the half will before the study time, Public take could in
second DPNCheck our Another launch device. generation upcoming milestone formal of is
We depend we the new components large customers. to chain. of in have supply pilot will confidence in will production we supply this before device our on challenging this We have The to be hope it once strategically environment. deploying market potential and ability the full launch highly year, meet goal follow started but the trials the end procure will in with
family web impact a will address that customers allow will analytics questions platform and based We the DPNCheck health related DPNCheck and utilization through cloud, a it customers starting is cloud XXXX. monitor launching population optimize is key launch DPNCheck DPNCheck expect dashboards. allow of by biosensor of Another end summer data of in milestone anticipate positively that and – implementation, which easily to our the
Although can directional do we the call. guidance earnings not last the provide reinforce financial guidance, in that we we provided
Quell the we XXXX the revenue domestic due counter other the revenue, advance in is a decrease of a expect by lacks increase business XXXX priorities. the as a driven business will that revenue, focus temporary terms continued overall downward offset to transitions to as relative in legacy growth the well from our to prescription over as trend which on attention neurotherapeutics, to This be partially it In DPNCheck of by business.
anticipate We initiatives. operating up in we the in have growth investments expect come Quell which DPNCheck, on and a resulting timing modest and increase reflecting relative a modest investment expenses I XXXX. loss will mostly in revenue net in growth these increase our noted, as due to And
Finally, income. to cash will due decrease negative
ATM at our to happy with not And of on the an questions planning we to expect prepared facility. year summarizes time, point. to opportunistic about end be million any this that at of sheet. balance we $XX and would this However, the we comments use And out execute are take financings
